Generic Ozempic Canada — When Is It Coming and What Will It Cost?
If you take Ozempic or you want to start semaglutide treatment, you probably have one question on your mind: when will a cheaper generic version arrive in Canada? The answer: much sooner than in the United States.
Canada is positioned to get generic semaglutide years before the U.S. Multiple pharmaceutical companies already have applications under review with Health Canada, and the first approvals could land as early as Q3 2026 (summer to early fall).
Below is a breakdown of the timeline, the companies racing to market, and what you can realistically expect to pay once generics hit pharmacy shelves.
Quick Verdict
| Detail | Summary |
|--------|--------|
| Expected availability | Q3 2026 (summer to early fall) |
| Estimated monthly cost | $100–$150 CAD with 3+ generics on market |
| Current Ozempic cost | $253–$310 CAD/month |
| Generic applications filed | 9 applications under Health Canada review |
| Key companies | Sandoz, Apotex, Vimy Pharma, Teva Canada, Taro, Aspen, Dr. Reddy's |
| Same effectiveness? | Yes. Generics must prove bioequivalence to get approval |
What Is Generic Ozempic?
Generic Ozempic contains the same active ingredient as brand-name Ozempic: semaglutide. It works the same way by mimicking GLP-1, a hormone that helps regulate blood sugar and appetite.
The key differences are:
- Manufacturer: A different company makes it instead of Novo Nordisk.
- Price: Generics are significantly cheaper once multiple competitors enter the market.
Health Canada requires every generic drug to demonstrate bioequivalence to the brand-name product. That means the generic must deliver the same amount of semaglutide into your bloodstream, at the same rate, as Ozempic.
If you currently take Ozempic for type 2 diabetes or weight management, a generic version will be expected to provide the same therapeutic effect at a lower cost. Your doctor can switch your prescription once a generic becomes available.
Why Canada Gets Generic Semaglutide Before the US
Two key events opened the door for Canadian generics:
- Data exclusivity expired on January 4, 2026.
Health Canada grants brand-name drugs eight years of data exclusivity. After that, generic manufacturers can reference the original clinical trial data in their own applications.
- Novo Nordisk let a key patent lapse.
Patent CA 2,890,222 covered semaglutide in Canada. Novo Nordisk did not pay the required maintenance fee, and the patent lapsed. Without that patent protection, generic companies face no patent barrier to making semaglutide in Canada.
In the United States, Novo Nordisk still holds patents that extend into the early 2030s, so American patients will likely wait years longer for affordable generics.
India already sells generic semaglutide for roughly $19 CAD per month, but Canadian prices will be higher due to regulatory, manufacturing, and distribution costs. Even so, the savings versus brand-name Ozempic in Canada should be substantial.
Which Companies Are Making Generic Semaglutide in Canada?
Health Canada is currently reviewing nine generic semaglutide applications. Key players include:
Sandoz
Sandoz, the generics division of Novartis, is one of the largest generic manufacturers globally. They initially targeted a first-half 2026 launch but now expect approval in Q3 2026 (July–September) after Health Canada requested additional data.
Sandoz has:
- Large-scale manufacturing capacity
- A strong distribution network across Canadian pharmacies
Apotex
Apotex is Canada’s largest generic pharmaceutical company, headquartered in Toronto. They have decades of experience with the Canadian regulatory system and already supply hundreds of generics to pharmacies nationwide. Their semaglutide application is under Health Canada review.
Vimy Pharma
Vimy Pharma is an Edmonton-based company co-founded by Farris Smith and Dave Suchon, both former executives at Novo Nordisk Canada. They manufacture at the Applied Pharmaceutical Innovation facility in Edmonton, which received $98 million in government funding.
CBC reported on their progress in March 2026. It’s a notable story: a Canadian company, built by people who helped bring Ozempic to Canada, now working to bring a generic version to market.
Teva Canada
Teva is one of the world’s largest generic drug makers. Its Canadian division has filed a semaglutide application with Health Canada. Teva brings global manufacturing scale and extensive regulatory experience.
Other Applicants
Additional applicants include:
- Taro Pharmaceuticals
- Aspen Pharmacare
- Dr. Reddy's Laboratories
With nine applications under review, competition should be strong once approvals begin, which is important for driving prices down under Canada’s generic pricing framework.
Timeline: When Will Generic Ozempic Be Available in Canada?
A realistic timeline based on current information:
- January 4, 2026 – Data exclusivity for semaglutide expired. Generic applications became eligible for review.
- January–March 2026 – Health Canada began reviewing the nine submitted applications. The standard review period is about 180 days.
- Q2 2026 (April–June) – Reviews continue. Some companies receive requests for additional data (as Sandoz did), which can extend individual timelines.
- Q3 2026 (July–September) – First approvals expected. Sandoz has publicly indicated they expect approval in this window. Other companies may receive approvals around the same time.
- Late 2026 – Multiple generics likely on pharmacy shelves, with competition pushing prices down.
Pharmaceutical policy researcher Mina Tadrous (University of Toronto) estimates that generic semaglutide will be available to patients by “summer or early fall” 2026. Clinicians like Dr. David Macklin at Medcan in Toronto report frequent patient questions about when generics will arrive.
What Will Generic Semaglutide Cost in Canada?
Canada uses a structured generic pricing framework that caps generic prices as a percentage of the brand price, depending on how many generics are on the market.
| Number of Generics | Maximum Price (% of Brand) | Estimated Monthly Cost (CAD) |
|--------------------|----------------------------|------------------------------|
| 1 generic approved | 75% of brand price | $190–$233 |
| 2 generics approved| 50% of brand price | $127–$155 |
| 3+ generics approved| 35% of brand price | $89–$109 |
With nine applications under review, it’s likely that three or more generics will be approved within the first year. That puts the realistic long-term price in the range of $100–$150 CAD per month, according to estimates from Mina Tadrous.
Compare that with current prices:
- Brand Ozempic: $253–$310 CAD/month
- Brand Wegovy: $540–$570 CAD/month
- Expected generic semaglutide: $100–$150 CAD/month (with 3+ competitors)
For many patients, that’s a savings of $100–$200 per month, or $1,200–$2,400 per year by switching from brand-name Ozempic to a generic.
Will Generic Semaglutide Work as Well as Ozempic?
Yes. Health Canada will not approve a generic semaglutide unless it demonstrates bioequivalence to Ozempic.